Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy.
about
Dopamine agonists for the treatment of cocaine dependenceDopamine agonists for the treatment of cocaine dependenceSelective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidinePharmacotherapy for stimulant-related disordersAgonist Medications for the Treatment of Cocaine Use DisorderPsychostimulant treatment of cocaine dependenceDecreased reinforcing effects of cocaine following 2 weeks of continuous D-amphetamine treatment in rats.The Health Effect of Psychostimulants: A Literature ReviewCompeting neurobehavioral decision systems theory of cocaine addiction: From mechanisms to therapeutic opportunities.Novel pharmacotherapeutic treatments for cocaine addiction.Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusersThe self-medication hypothesis and psychostimulant treatment of cocaine dependence: an updateMethamphetamine self-administration in humans during D-amphetamine maintenance.Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THCEffects of chronic d-amphetamine administration on the reinforcing strength of cocaine in rhesus monkeysReduction of the reinforcing effectiveness of cocaine by continuous D-amphetamine treatment in rats: importance of active self-administration during treatment periodPhysiological and subjective effects of acute intranasal methamphetamine during atomoxetine maintenance.Physiological and subjective effects of acute intranasal methamphetamine during extended-release alprazolam maintenance.Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.Agonist replacement therapy for cocaine dependence: a translational review.Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants.Assessment of the impact of pattern of cocaine dosing schedule during conditioning and reconditioning on magnitude of cocaine CPP, extinction, and reinstatement.The effects of oral d-amphetamine on impulsivity in smoked and intranasal cocaine users.Buspirone reduces sexual risk-taking intent but not cocaine self-administration.Cocaine versus food choice procedure in rats: environmental manipulations and effects of amphetamine.Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.Drugs currently in Phase II clinical trials for cocaine addiction.Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy.Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys.Methamphetamine Cured my Cocaine Addiction.The potential of pharmacogenomics to treat drug addiction.
P2860
Q24187799-C09D51BF-9C12-45A0-82DA-080A25DFA9D8Q24234240-93F41BF5-BF79-42C5-9EF8-E9DD91930011Q24657405-616B1E25-2649-4A32-B7A8-6FCACD26F10AQ26829186-D14187F3-425D-4F0E-90BC-159B25CD21A4Q28087404-B52EFDD3-E5C3-4BAF-9E61-0F57D24757F5Q28267550-B7A54A0F-A899-4456-B7C3-49812CB92984Q30479418-12DE35E6-229E-43D5-B7A7-67B32F653555Q33677986-90B31083-82FF-4F2F-8D49-00B7EA105E0FQ33865481-B0906D31-3EA9-4890-BA35-DC7C5DB8A1D6Q34065088-9CDA2FA4-E92F-40C5-AE77-BB7083D91B2AQ34253787-FABF4416-C91D-426F-BE64-FE5E153F08E1Q34300251-4C1A4477-FA6C-430E-80A3-B097004FA75DQ34487773-B7FB7F89-06D2-45B2-AFAB-F888B15C8B3EQ34550457-86C22815-D89D-4D1F-8C5B-C8C88BF333AAQ34950909-9971A58C-6DB9-4CD9-B2D5-0A1ECE2766B8Q35065338-D1F58527-D2C7-4E8C-AB52-F3F7C1D95A80Q35082614-3823A770-C7EB-4623-A1CD-66FA03982949Q35242878-B80B81C8-7D47-4E44-8DB0-2062C8B810AAQ35257856-E0432B80-B456-465E-9249-9F28AAA4B44EQ35576598-700BA41F-60AC-408A-8B19-E0AEB7FDA282Q35799846-D9CEA531-1EC3-4098-B514-EE3DB102B481Q36381407-B7205D31-52A3-40CB-8EBB-917ACD25C853Q36759379-458915BA-946D-45D5-8777-7075AB1728A7Q36936174-EC8B011A-5B23-4489-BFF5-1AF4E298D9F3Q36976585-8269E07F-A425-4B60-84FE-F1850DE5DD1CQ37484687-F982BFD7-FF4B-4022-AC4E-7AD34F86B9AEQ37625841-FF730E53-B89F-437A-AB17-E623ADAFD56AQ38207705-3D20CB79-41CF-4045-B286-C41CBD7F2B79Q38271498-30E8121B-3A5D-427A-82C4-3DF8E065312BQ42230716-71D4EEEE-72C8-419C-B60E-2027FBEBDE39Q42431777-A69EBF87-77F7-43C5-9270-C97898572426Q52295623-6B17DFC1-7C93-45E2-9FCE-96AADC8ADC18
P2860
Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cocaine effects during D-amphe ...... ty, tolerability and efficacy.
@en
Cocaine effects during D-amphe ...... ty, tolerability and efficacy.
@nl
type
label
Cocaine effects during D-amphe ...... ty, tolerability and efficacy.
@en
Cocaine effects during D-amphe ...... ty, tolerability and efficacy.
@nl
prefLabel
Cocaine effects during D-amphe ...... ty, tolerability and efficacy.
@en
Cocaine effects during D-amphe ...... ty, tolerability and efficacy.
@nl
P2093
P2860
P1476
Cocaine effects during D-amphe ...... ty, tolerability and efficacy.
@en
P2093
Craig R Rush
Lon R Hays
William W Stoops
P2860
P304
P356
10.1016/J.DRUGALCDEP.2008.08.009
P577
2008-10-15T00:00:00Z